Literature DB >> 15346343

Intrathecal production and secretion of vascular endothelial growth factor during Cryptococcal Meningitis.

Frank E J Coenjaerts1, Michiel van der Flier, Pauline N M Mwinzi, Annemarie E Brouwer, Jelle Scharringa, Wendy S Chaka, Marieke Aarts, Adul Rajanuwong, David A van de Vijver, Tom S Harrison, Andy I M Hoepelman.   

Abstract

BACKGROUND: Patients with cryptococcal meningitis (CM) show elevated intracranial pressure (ICP) and blood-brain barrier (BBB) disruption in most cases. Elevated ICP is an important contributor to mortality. Vascular endothelial growth factor (VEGF) might be the mediator of BBB disruption during CM.
METHODS: We measured VEGF levels in serum, plasma, and cerebrospinal fluid (CSF) of 95 patients and 63 control subjects, and we analyzed the required trigger and cellular source of VEGF secretion in vitro.
RESULTS: Cryptococcus neoformans and its capsular antigens dose-dependently induced VEGF secretion by polymorphonuclear neutrophils, monocytes, and peripheral blood mononuclear cells (PBMCs). VEGF production by PBMCs induced by antigens strongly exceeded production by monocytes (P<.001). The addition of major histocompatibility complex class II antibody inhibited this production of VEGF (P=.005). Confirming the in vitro data, patients with CM showed significantly elevated VEGF levels in CSF (P<.001), plasma (P=.028), and serum (P<.001), compared with healthy control subjects. Calculated VEGF indices demonstrated that VEGF was produced intrathecally.
CONCLUSIONS: Our findings suggest that VEGF plays a role in the pathophysiology of CM. We propose that CD4(+) T lymphocytes--stimulated by monocytes acting as antigen-presenting cells--are the cells that produce VEGF in response to cryptococcal antigens.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15346343     DOI: 10.1086/423849

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  The detection of vascular endothelial growth factor in serum of patients with hemorrhagic fever with renal syndrome.

Authors:  Man Li; Yuqiang Ji; Yanying Dong; Yan Zhou; Huixun Ren; Ming Xie
Journal:  Inflammation       Date:  2013-08       Impact factor: 4.092

2.  Evidence of a role for monocytes in dissemination and brain invasion by Cryptococcus neoformans.

Authors:  Caroline Charlier; Kirsten Nielsen; Samira Daou; Madly Brigitte; Fabrice Chretien; Françoise Dromer
Journal:  Infect Immun       Date:  2008-10-20       Impact factor: 3.441

3.  The role of angiogenic factors in predicting clinical outcome in severe bacterial infection in Malawian children.

Authors:  Limangeni A Mankhambo; Daniel L Banda; Graham Jeffers; Sarah A White; Paul Balmer; Standwell Nkhoma; Happy Phiri; Elizabeth M Molyneux; C Anthony Hart; Malcolm E Molyneux; Robert S Heyderman; Enitan D Carrol
Journal:  Crit Care       Date:  2010-05-21       Impact factor: 9.097

4.  Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study.

Authors:  David R Boulware; David B Meya; Tracy L Bergemann; Darin L Wiesner; Joshua Rhein; Abdu Musubire; Sarah J Lee; Andrew Kambugu; Edward N Janoff; Paul R Bohjanen
Journal:  PLoS Med       Date:  2010-12-21       Impact factor: 11.069

5.  Inflammatory responses to infection: the Dutch contribution.

Authors:  Martijn A Nolte; Jos W M van der Meer
Journal:  Immunol Lett       Date:  2014-10-18       Impact factor: 3.685

6.  Delayed progression of edema formation around a hematoma expressing high levels of VEGF and mmp-9 in a patient with traumatic brain injury: case report.

Authors:  Tomoya Hirose; Naoya Matsumoto; Osamu Tasaki; Hajime Nakamura; Fuyuko Akagaki; Takeshi Shimazu
Journal:  Neurol Med Chir (Tokyo)       Date:  2013       Impact factor: 1.742

7.  Treatment and outcomes among patients with Cryptococcus gattii infections in the United States Pacific Northwest.

Authors:  Rachel M Smith; Adamma Mba-Jonas; Mathieu Tourdjman; Trisha Schimek; Emilio DeBess; Nicola Marsden-Haug; Julie R Harris
Journal:  PLoS One       Date:  2014-02-19       Impact factor: 3.240

8.  CryptoDex: a randomised, double-blind, placebo-controlled phase III trial of adjunctive dexamethasone in HIV-infected adults with cryptococcal meningitis: study protocol for a randomised control trial.

Authors:  Jeremy Day; Darma Imran; Ahmed Rizal Ganiem; Natriana Tjahjani; Retno Wahyuningsih; Robiatul Adawiyah; David Dance; Mayfong Mayxay; Paul Newton; Rattanaphone Phetsouvanh; Sayaphet Rattanavong; Adrienne K Chan; Robert Heyderman; Joep J van Oosterhout; Wirongrong Chierakul; Nick Day; Anatoli Kamali; Freddie Kibengo; Eugene Ruzagira; Alastair Gray; David G Lalloo; Justin Beardsley; Tran Quang Binh; Tran Thi Hong Chau; Nguyen Van Vinh Chau; Ngo Thi Kim Cuc; Jeremy Farrar; Tran Tinh Hien; Nguyen Van Kinh; Laura Merson; Lan Phuong; Loc Truong Tho; Pham Thanh Thuy; Guy Thwaites; Heiman Wertheim; Marcel Wolbers
Journal:  Trials       Date:  2014-11-12       Impact factor: 2.279

9.  Do Intracerebral Cytokine Responses Explain the Harmful Effects of Dexamethasone in Human Immunodeficiency Virus-associated Cryptococcal Meningitis?

Authors:  Justin Beardsley; Nhat L T Hoang; Freddie M Kibengo; Nguyen L N Tung; Tran Q Binh; Le Q Hung; Wirongrong Chierakul; Guy E Thwaites; Nguyen V V Chau; Thuong T T Nguyen; Ronald B Geskus; Jeremy N Day
Journal:  Clin Infect Dis       Date:  2019-04-24       Impact factor: 9.079

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.